Efficacy and Safety of Erythromycin in the Treatment of Mycoplasma Pneumonia in Children: A Systematic Review and Meta-Analysis
Abstract
Aim The effectiveness and safety of erythromycin for treating mycoplasma pneumonia in pediatric patients is a subject of significant interest. This study aims to conduct a systematic review and meta-analysis to assess the efficacy and safety of erythromycin in the treatment of mycoplasma pneumonia in children,with the goal of providing evidence-based recommendations for pediatric care. Methodology We systematically reviewed randomized controlled trials published prior to January 1, 2024, that evaluated the efficacy and safety of erythromycin in the treatment of mycoplasma pneumonia in children. Outcome measures of primary concern include clinical efficacy, complications or adverse events. We used the inverse variance method to perform a meta-analysis of random effects, representing the effects in terms of Standardized Mean Difference (SMD) or Mean Difference (MD) and giving a 95% Confidence Interval (CIs). In addition, we performed a risk assessment of bias using the Cochrane tool. A total of 68 relevant studies were searched and 4 literatures meeting the requirements were included, with a total of 599 children. Results The results of meta-analysis showed that the efficacy of erythromycin in the treatment of mycoplasma pneumonia in children was not statistically significant compared with conventional treatment [RR=12.31, 95%CI (-1.23, 25.86)]. The safety of erythromycin in the treatment of mycoplasma pneumonia in children was significantly different from that of conventional…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid. Reported size: 599 participants or records.
Read the paper
Related studies
- Penicillins for Treatment of Pneumococcal Pneumonia: Does In Vitro Resistance Really Matter?
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Development and validation of microbial bioassay for quantification of Levofloxacin in pharmaceutical preparations
- GC-MS Analysis and Biomedical Therapy of Oil from n-Hexane Fraction of Scutellaria edelbergii Rech. f.: In Vitro, In Vivo, and In Silico Approach
- Propranolol, chlorpromazine and diclofenac restore susceptibility of extensively drug-resistant (XDR)-Acinetobacter baumannii to fluoroquinolones
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.